Curis (CRIS) Gets a Buy Rating from B.Riley Financial

B.Riley Financial analyst Justin Walsh reiterated a Buy rating on Curis (CRISResearch Report) today and set a price target of $22.00. The company’s shares closed last Friday at $3.46.

According to TipRanks.com, Walsh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -35.4% and a 8.3% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Fusion Pharmaceuticals, and Eton Pharmaceuticals.

Curis has an analyst consensus of Strong Buy, with a price target consensus of $21.00, implying a 476.9% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.

See the top stocks recommended by analysts >>

Curis’ market cap is currently $320.2M and has a P/E ratio of -7.58.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170, and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Read More on CRIS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed